Intention-to-Treat (ITT) Analysis

In Detail

Intention-to-treat (ITT) analysis is a statistical methodology in which all participants in a clinical trial are analyzed according to the group they were originally randomized to, regardless of whether they actually received the treatment, completed the study, or adhered to the protocol. If a participant assigned to the treatment group stops taking the drug but remains in the study, their outcomes are still counted in the treatment group. The ITT principle preserves the integrity of randomization and prevents bias that could result from selectively excluding participants whose outcomes might unfavorably affect the results. This approach reflects real-world conditions more accurately because in clinical practice, patients do not always take their medications as prescribed or complete their treatment courses. ITT analysis provides a conservative estimate of the treatment's effect — it tends to dilute the apparent benefit because it includes participants who may not have received adequate treatment. For this reason, ITT analysis is considered the primary analysis method by most regulatory agencies and is required by the FDA for pivotal trials. However, ITT analysis has limitations: if a large proportion of participants drop out or switch treatments, the ITT results may underestimate the true efficacy of the treatment in patients who actually take it. To address this, researchers often conduct a per-protocol analysis alongside the ITT analysis. The ITT population must be clearly defined in the statistical analysis plan, and the handling of missing data from participants who discontinue must be pre-specified using validated methods such as last observation carried forward or multiple imputation.